Saturday 17 October 2026
Export JNJ’s income statement to Excel — free account
Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
255.55
2.27
+0.90%
Follow JNJ
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 25.74% | 26.42% | 35.03% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
— | 6 | 4 | 4 | |
| 0.00% | 10.67% | 10.66% | 14.13% | ||
ROIC |
0.00% | 15.51% | 16.13% | 20.19% | |
Return on Tangible Assets |
0.00% | 73.92% | 85.09% | 108.66% | |
Average Days of Receivables |
0.00 | 70.99 | 67.12 | 66.57 | |
Free Cash Flow per Share |
— | 9.44 | 7.58 | 8.48 | |
Free Cash Flow |
— | 22,724.00 | 18,254.00 | 20,418.00 | |
Capital Expenditures |
— | (4,884.00) | (4,616.00) | (4,112.00) | |
| Other line items | |||||
Cash ROIC |
— | 15.88% | 12.97% | 14.47% | |
Accounts Receivable Turnover |
0.00 | 5.31 | 5.71 | 5.88 | |
Accounts Payable Turnover |
0.00 | 3.36 | 3.10 | 2.71 | |
Inventory Turnover |
0.00 | 2.20 | 2.28 | 2.27 | |
Average Days of Payables |
0.00 | 107.11 | 123.14 | 144.66 | |
Days of Inventory on Hand |
0.00 | 175.88 | 171.68 | 171.20 | |
Tax Rate |
(0.09) | (0.17) | (0.16) | (0.18) | |
Research and Development Expense of Revenue |
16.19% | 15.42% | 15.53% | 15.57% | |
Selling, General and Administrative Expense of Revenue |
25.67% | 25.67% | 25.53% | 25.14% | |
Share Based Compensation of Revenue |
0.00% | 1.44% | 1.42% | 1.44% | |
Interest Coverage |
— | 26.80 | 25.92 | 35.64 | |
Operating CF/Net income |
0.00 | 1.31 | 1.09 | 0.92 | |
Depreciation/Fixed assets |
— | 0.33 | 0.33 | 0.32 | |
Capex/Depreciation |
— | (0.63) | (0.60) | (0.55) | |
Revenue per Share |
0.00 | 40.68 | 40.01 | 39.13 | |
Operating CF per Share |
— | 11.47 | 9.49 | 10.19 | |
Capex per Share |
— | (2.03) | (1.92) | (1.71) | |
Capex to Sales |
0.00 | 0.05 | 0.05 | 0.04 |
Columns are period end dates · fundamentals updated 14 Oct 2026